China Nuokang Bio-Pharmaceutical Inc. Adjourns Extraordinary General Meeting of Shareholders
15 January 2013 - 8:00PM
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or
the "Company") announced today that it has adjourned its
extraordinary general meeting of shareholders that was called to
authorize and approve the proposed merger with an affiliate of
Kingbird Investment Inc. ("Parent"), an affiliate of Mr. Baizhong
Xue, the Chairman and Chief Executive Officer of the Company,
pursuant to the agreement and plan of merger dated as of September
27, 2012, among the Company, Parent and Kingbird Mergerco. Inc.
("Merger Sub"), and, solely for the purposes of Section 6.16
thereof, Anglo China Bio-technology Investment Holdings Limited and
Britain Ukan Technology Investment Holdings (Group) Limited. Parent
has advised the Company that it requires additional time to obtain
its contemplated debt financing for the pending transaction. Apart
from the motion to adjourn, no other business was conducted at the
extraordinary general meeting of shareholders on January 15, 2013.
The resolutions set out in the notice of the extraordinary general
meeting dated December 17, 2012 will be considered and voted on at
such time as the adjourned extraordinary general meeting is
resumed. The Company intends to resume the adjourned extraordinary
general meeting of shareholders as soon as practicable following
confirmation from Parent that the debt financing will be available
at the closing of the transaction, and Parent has further advised
the Company that it expects this will not be later than March 21,
2013. The Company will give notice to shareholders of the date on
which the adjourned extraordinary general meeting will be resumed
as soon as a date is selected, and in any event not less than seven
calendar days prior to such resumed meeting.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading
biopharmaceutical company in China focused on the research,
development, manufacture, marketing and sales of hospital-based
medical products. The Company provides a diversified portfolio of
products across more than 4,200 hospitals in China Nuokang's
principal products include Baquting®, China's leading hemocoagulase
product by market share, Kaitong®, a lipid emulsion alprostadil
product for the treatment of peripheral vascular diseases,
cardiocerebral microcirculation disorders and post-surgery
thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant
product that addresses diabetic neuropathy. The Company's product
pipeline includes product candidates under development in
hematological, cardiovascular and cerebrovascular disease
diagnosis, treatment and prevention. Please visit www.nkbp.com for
more information.
Forward-Looking Statements
This press release contains forward-looking statements relating
to the potential acquisition of the Company by an affiliate of Mr.
Baizhong Xue, the Chairman and Chief Executive Officer of the
Company. These are "forward-looking" statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and
as defined in the U.S. Private Securities Litigation Reform Act of
1995. The actual results of the transaction could vary materially
as a result of a number of factors, including: uncertainties as to
how the Company's shareholders will vote at the extraordinary
general meeting; the possibility that competing offers will be
made; and the possibility that various closing conditions for the
transaction may not be satisfied or waived. These forward-looking
statements reflect the Company's expectations as of the date of
this press release. The Company does not undertake any obligation
to update any forward-looking statement, except as required under
applicable law.
CONTACT: China Nuokang Bio-Pharmaceutical Inc.
Mr. Steven Duan
Vice President of Investor Relations
Email: dsz@nkbp.com
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 or (646) 405-5180
Email: robert.koepp@icrinc.com
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From Jul 2023 to Jul 2024